Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$41.71 USD

41.71
3,332,734

+0.28 (0.68%)

Updated Aug 23, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sangamo Therapeutics Initiates Dosing in Hemophilia A Study

by Zacks Equity Research

Sangamo Therapeutics (SGMO) and partner Pfizer announced the dosing of first patient in Alta study on Hemophilia A candidate, SB-525.

    Novartis (NVS) Receives EC Approval for Breast Cancer Drug

    by Zacks Equity Research

    Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.

      Arpita Dutt headshot

      Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug

      by Arpita Dutt

      It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.

        Celldex Ends Phase II Enrollment for Breast Cancer Candidate

        by Zacks Equity Research

        Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.

          Roche (RHHBY) Hemophilia A Drug Granted Priority Review

          by Zacks Equity Research

          Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.

            BioLineRx Moves a Regulatory Submission for BL-8040 Trial

            by Zacks Equity Research

            BioLineRx (BLRX) forwards a regulatory submission to begin a phase III study to evaluate BL-8040 in combination with G-CSF for treatment of multiple myeloma.

              Arpita Dutt headshot

              Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why

              by Arpita Dutt

              Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis ("MS") drugs.

                Mylan Finalizes Settlement Agreement with DOJ for $465M

                by Zacks Equity Research

                Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017.

                  Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx

                  by Zacks Equity Research

                  Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.

                    Ophthotech's Fovista Combo Regimen Disappoints in Phase III

                    by Zacks Equity Research

                    Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.

                      Bristol-Myers Opdivo Fails Kidney Cancer Trial CheckMate-214

                      by Zacks Equity Research

                      Bristol-Myers Squibb Company (BMY) announced disappointing top-line results from the CheckMate-214 trial on Opdivo in renal cell carcinoma.

                        Puma (PBYI) Q2 Loss Narrower than Expected, Nerlynx in Focus

                        by Zacks Equity Research

                        Puma Biotechnology (PBYI) reported narrower-than-expected loss in Q2. Shares were down in after-hours trading.

                          Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View

                          by Zacks Equity Research

                          Mylan N.V. (MYL) reported disappointing second-quarter 2017 results wherein both earnings and sales missed estimates. The company also lowered its guidance.

                            Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat

                            by Zacks Equity Research

                            Inovio Pharmaceuticals (INO) reports narrower-than-expected loss with revenue beating estimates. Moreover, the top line significantly increases year over year.

                              Prothena (PRTA) Q2 Loss Narrows as Roche Makes $30M Payment

                              by Zacks Equity Research

                              Prothena Corporation plc (PRTA) reported a narrower-than-expected loss in the second quarter as the company received a milestone payment from Roche.

                                Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up

                                by Zacks Equity Research

                                Kite Pharma, Inc. (KITE) reported narrower-than-expected loss in the second quarter of 2017 and beat estimates for sales. Shares of the biotech company rose 5.8% on Tuesday.

                                  Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2

                                  by Zacks Equity Research

                                  Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat.

                                    What's in the Cards for Kite Pharma (KITE) in Q2 Earnings

                                    by Zacks Equity Research

                                    With no approved products in its portfolio, investor focus will primarily be on Kite Pharma, Inc.'s (KITE) cash burn and pipeline updates.

                                      Exelixis (EXEL) Q2 Earnings, Sales Beat on Cabometyx Sales

                                      by Zacks Equity Research

                                      Exelixis' (EXEL) second-quarter results were impressive where in both earnings and sales beat estimates driven by strong uptake of Cabometyx.

                                        Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2

                                        by Zacks Equity Research

                                        Immune Design (IMDZ) incurred narrower-than-expected loss in Q2. Revenues missed expectations.

                                          Clovis (CLVS) Q2 Loss Wider than Expected, Rubraca Impresses

                                          by Zacks Equity Research

                                          Clovis Oncology (CLVS) reported narrower year-over-year loss in the second quarter on the back of impressive Rubraca sales. The company is also actively working on Rubraca's label expansion.

                                            Mylan (MYL) to Report Q2 Earnings: What's in the Cards?

                                            by Zacks Equity Research

                                            Mylan N.V. (MYL) is expected to focus on the performance of EpiPen and progress with the biosimilars pipeline during its second-quarter results.

                                              What to Expect from Epizyme (EPZM) This Earnings Season?

                                              by Zacks Equity Research

                                              Epizyme, Inc. (EPZM) plans to focus on the development of its lead candidate tazemetostat in Q2.

                                                Swarup Gupta headshot

                                                Foreign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings

                                                by Swarup Gupta

                                                Investors across the globe focused on earning numbers and the outcome of the Fed's policy meeting this week.

                                                  ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up

                                                  by Zacks Equity Research

                                                  ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.